$1.400
-0.136 (-9.68%)收盘时
PACB 资讯
PACB 事件
PacBio Appoints Mark Van Oene as New CEO
PacBio announced that its board of directors has appointed Mark Van Oene as president and CEO, effective August 5. Van Oene, who has served as COO, succeeds Christian Henry, who has stepped down as president and CEO after six years leading PacBio. Van Oene has also been appointed to serve on PacBio's board of directors, effective August 5. Henry will continue to serve on PacBio's board of directors and has agreed to serve as a business advisor to the company at least through the end of 2026, in order to facilitate a transition. Van Oene joined PacBio in 2021 as COO.
Company Reports Q2 Revenue of $39M, Below Consensus
Reports Q2 revenue $39M, consensus $40.58M.
PacBio Expects 2026 Revenue Between $155M and $165M
Consensus $167.43M. The company said, "PacBio expects revenue for the full year 2026 to be in the range of $155 million to $165 million."
PacBio Launches SPRQ-Nx Sequencing Chemistry, Genome Price at $345
PacBio announced that SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for its Revio HiFi sequencing platform are now shipping worldwide. The commercial availability of SPRQ-Nx brings the per genome list price to $345, and the possibility of sub-$300 HiFi genomes to Revio customers sequencing at scale, while expanded methylation detection and advances to DeepConsensus.
Blank Bio Closes $7.2M Seed Financing
Blank Bio announced the closing of a $7.2M seed financing and a strategic collaboration with Pacific Biosciences. Blank Bio is building RNA foundation models that learn directly from the molecular complexity of tumor transcriptomes to improve patient-level prediction across oncology. Proceeds from the financing will support continued model development, expanded collaborations with pharmaceutical and diagnostic companies, and new long-read RNA-seq datasets to support applications in biomarkers, clinical trial design, and diagnostics.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。